2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...

Compared with DPP-4 inhibitors, SGLT2 inhibitors and GLP-1RAs conferred lower risks for COPD exacerbation among patients with type 2 diabetes. Among patients with type 2 diabetes (T2D) and active ...

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

A new study published in the journal of BMC Pulmonary Medicine showed that dyspnea (mMRC score 1.67), symptom load (CAT score ...

For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or ...

3 Beta-adrenergic agonists are frequently used in the management of acute chronic obstructive pulmonary disease (COPD) exacerbations due to their bronchodilatory effects. However, they can also have ...

Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for ...

After news that Louisville failed a national ranking for high rates of particle and ozone pollution, a UofL researcher says ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

congress – showed that the anti-TSLP-antibody wasn’t able to achieve a statistically significant reduction in the annual rate of moderate to severe COPD exacerbations compared to placebo.

FEV1 helps measure the progression of lung conditions such as chronic obstructive pulmonary disease (COPD) or asthma. FEV stands for forced expiratory volume, which is the air you exhale in one ...